Roche Holding AG Market Cap 2010-2024 | RHHBY

Roche Holding AG market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Roche Holding AG market cap as of July 08, 2025 is $255.69B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $255.691B $68.726B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $737.016B 56.52
Johnson & Johnson (JNJ) United States $374.842B 15.50
AbbVie (ABBV) United States $335.210B 18.48
Novo Nordisk (NVO) Denmark $310.943B 20.60
Novartis AG (NVS) Switzerland $257.040B 14.68
Merck (MRK) United States $204.323B 10.44
Pfizer (PFE) United States $145.659B 7.98
Sanofi (SNY) France $118.160B 11.64
Bayer (BAYRY) Germany $31.320B 6.38
Innoviva (INVA) United States $1.196B 12.54